GALAPAGOS NV (GLPG.AS) Stock Price, Forecast & Analysis
Europe - Euronext Amsterdam - AMS:GLPG - BE0003818359 - Common Stock
GLPG.AS Key Statistics, Chart & Performance
The current stock price of GLPG.AS is 28.35 EUR. In the past month the price increased by 4.19%. In the past year, price increased by 13.01%.
GLPG.AS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 65.62 | 43.02B | ||
| 1AE.DE | ARGENX SE | 65.41 | 42.89B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.32B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.78B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.72B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.87B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| NANO.PA | NANOBIOTIX | N/A | 848.59M | ||
| IVA.PA | INVENTIVA SA | N/A | 773.62M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20 | 666.67M | ||
| FYB.DE | FORMYCON AG | N/A | 458.54M |
Related stock screener links
About GLPG.AS
Company Profile
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 704 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Company Info
GALAPAGOS NV
Generaal De Wittelaan L11 A3
MALINES (MECHELEN) ANTWERPEN BE
Employees: 704
Phone: 3215342900
GALAPAGOS NV / GLPG.AS FAQ
What does GLPG do?
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 704 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Can you provide the latest stock price for GALAPAGOS NV?
The current stock price of GLPG.AS is 28.35 EUR. The price increased by 0.11% in the last trading session.
Does GLPG stock pay dividends?
GLPG.AS does not pay a dividend.
What is the ChartMill rating of GALAPAGOS NV stock?
GLPG.AS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists GLPG stock?
GLPG.AS stock is listed on the Euronext Amsterdam exchange.
How is the valuation of GALAPAGOS NV (GLPG.AS) based on its PE ratio?
GALAPAGOS NV (GLPG.AS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.62).
GLPG.AS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to GLPG.AS. When comparing the yearly performance of all stocks, GLPG.AS turns out to be only a medium performer in the overall market: it outperformed 47.89% of all stocks.
GLPG.AS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLPG.AS. While GLPG.AS seems to be doing ok healthwise, there are quite some concerns on its profitability.
GLPG.AS Financial Highlights
Over the last trailing twelve months GLPG.AS reported a non-GAAP Earnings per Share(EPS) of -6.62. The EPS decreased by -311.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.41% | ||
| ROE | -17.82% | ||
| Debt/Equity | 0 |
GLPG.AS Forecast & Estimates
19 analysts have analysed GLPG.AS and the average price target is 30.74 EUR. This implies a price increase of 8.42% is expected in the next year compared to the current price of 28.35.
For the next year, analysts expect an EPS growth of -541.12% and a revenue growth -5.4% for GLPG.AS